Management for high serum ig E

Reading File

Finding Sources

Searching PubMed

"elevated IgE" OR "hyper IgE" management treatment

Reading File

Finding Sources

Reading File

Finding Sources

I now have comprehensive information to give a thorough answer. Let me compile everything.

Management of High Serum IgE

Elevated serum IgE is not a single disease — it is a biomarker associated with multiple underlying conditions. Management is therefore cause-directed, with general and targeted therapies depending on the etiology.

Step 1: Identify the Underlying Cause

Causes of elevated serum IgE (normal adult: < 100–150 IU/mL):

Category	Examples
Atopic diseases	Allergic asthma, allergic rhinitis, atopic dermatitis, food allergy
Parasitic infections	Helminths (Ascaris, hookworm, schistosomiasis, toxocariasis)
Fungal disease	Allergic bronchopulmonary aspergillosis (ABPA) — IgE > 1000 IU/mL is an essential criterion
Primary immunodeficiency	Hyper-IgE syndromes (HIES/Job's syndrome), Wiskott-Aldrich syndrome
Malignancy	IgE myeloma (rare), some T-cell lymphomas
Other	Netherton syndrome, CADINS, Omenn syndrome

2. Management by Cause

A. Atopic Disease (Asthma, Eczema, Rhinitis)

General measures

Allergen avoidance — identify and avoid triggers
Antihistamines (H1 blockers) — relieve urticaria, rhinitis, mild allergic symptoms
Topical/inhaled corticosteroids — suppress chronic inflammation in asthma and eczema
Leukotriene receptor antagonists (e.g., montelukast) — adjunct in asthma and rhinoconjunctivitis
β₂-agonists (inhaled) — bronchodilation in asthma

Allergen immunotherapy (desensitization)

Subcutaneous or sublingual administration of specific antigen induces regulatory T cells and shifts toward tolerance
Reduces IgE-mediated sensitization over time

— Janeway's Immunobiology 10e

Biologic therapy — Omalizumab (anti-IgE)

The cornerstone targeted therapy for IgE-mediated disease:

Mechanism: Humanized monoclonal antibody that binds the Fc region of IgE, blocking binding to:
- High-affinity receptors (FcεRI) on mast cells → prevents allergen-triggered degranulation
- Low-affinity receptors (FcεRII/CD23) on B cells, T cells, macrophages → suppresses chronic inflammation
- Also reduces FcεRI expression on dendritic cells and enhances type I interferon response to rhinovirus
Dose: Subcutaneous injection every 2–4 weeks; dose determined by baseline total IgE level and body weight
Indications: Severe allergic asthma poorly controlled on high-dose ICS ± oral corticosteroids; severe chronic urticaria; ABPA
Efficacy: >50% excellent response in adults and children with severe asthma; reduces exacerbations, oral steroid requirement, and circulating IgE levels
Predictors of response: High blood eosinophils and elevated FeNO suggest better response; a 4-month trial is required as no clear upfront predictor exists
Side effect: Anaphylaxis (<0.1%) — observe patients post-injection

— Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 44

Other biologics (for type 2/eosinophilic inflammation)

Anti-IL-5: Mepolizumab, reslizumab (block IL-5); benralizumab (blocks IL-5Rα) — for severe eosinophilic asthma
Dupilumab (anti-IL-4Rα, blocks IL-4/IL-13 signaling) — approved for atopic dermatitis, asthma, nasal polyps; also shown effective in HIES-related eczema

B. Hyper-IgE Syndrome (HIES / Job's Syndrome)

A primary immunodeficiency caused by dominant-negative STAT3 mutations (or DOCK8 deficiency), with triad of:

Recurrent sinopulmonary + cutaneous infections (Staph, Candida, Aspergillus)
Eczematous dermatitis from infancy
Markedly elevated IgE (often > 2000 IU/mL)

Management

Intervention	Details
Prophylactic antibiotics	TMP-SMX (trimethoprim-sulfamethoxazole) 160/800 mg BD to prevent recurrent bacterial infections
Antifungals	Fluconazole, itraconazole, voriconazole for mucocutaneous candidiasis
Abscess management	Incision and drainage + prolonged antibiotic courses (unusual organisms must be suspected)
IFN-γ	Controls infections; reduces severity of recurrent infections
IVIg	May improve dermatitis, prevent infections, and lower IgE levels
Dupilumab	Reported to improve eczematous dermatitis in HIES
Omalizumab	Reported to improve eczematous dermatitis in HIES
Hematopoietic stem cell transplantation (HSCT)	Potentially curative for DOCK8 deficiency and selected severe cases; improves outcomes in AR forms
Dental management	Primary teeth often fail to exfoliate → may require extraction

— Dermatology 2-Volume Set 5e, Ch. 60; Harrison's Principles of Internal Medicine 22E

C. Allergic Bronchopulmonary Aspergillosis (ABPA)

Essential criterion: Total IgE > 1000 IU/mL + specific IgE/IgG to Aspergillus fumigatus
Treatment:
- Oral corticosteroids (prednisolone) — mainstay; suppress inflammatory response to Aspergillus
- Itraconazole — azole antifungal as steroid-sparing agent
- Omalizumab — beneficial in steroid-dependent ABPA
- Monitor IgE levels serially: fall in IgE indicates response; rise indicates relapse

D. Parasitic Infection

Anthelmintic therapy: Albendazole or mebendazole (soil-transmitted helminths), praziquantel (schistosomiasis) — treats the underlying cause and IgE typically falls post-treatment
No role for anti-IgE biologics here

3. Monitoring IgE Levels

Serial total IgE is used to monitor disease activity (especially in ABPA, HIES)
Omalizumab raises measured total IgE (bound + unbound), so IgE cannot be used to monitor response during treatment — use clinical endpoints instead

Summary Table

Condition	First-Line	IgE-Specific Therapy
Allergic asthma	ICS + LABA	Omalizumab (severe)
Atopic dermatitis	Topical CS, emollients	Dupilumab; omalizumab
Allergic rhinitis	Intranasal CS, antihistamines	Immunotherapy
ABPA	Oral prednisolone + itraconazole	Omalizumab
HIES (Job's)	TMP-SMX prophylaxis + antifungals	Dupilumab, IVIg
Helminths	Anthelmintics	Not applicable
Anaphylaxis	Epinephrine (acute)	Omalizumab (prevention)

Key clinical pearl: Omalizumab dosing is weight- and IgE-titered (not exceeding IgE > 1500 IU/mL for standard dosing); always confirm baseline IgE before prescribing. — Goodman & Gilman's, p. 2979

Create a treatment protocol document for IgE-lowering therapies

Reading File

Running Command

mkdir -p /home/daytona/workspace/ige-protocol && ls /home/daytona/workspace/ige-…

Writing File

~/ige-protocol/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, TableOfContents,
  PageBreak, UnderlineType
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────
const NAVY    = "1B3A6B";
const TEAL    = "0E7C7B";
const LTBLUE  = "D6EAF8";
const LTGREY  = "F2F3F4";
const WHITE   = "FFFFFF";
const DARK    = "1A1A2E";
const ORANGE  = "E67E22";
const GREEN   = "1E8449";

// ── Helpers ──────────────────────────────────────────────────────
function hRun(text, opts = {}) {
  return new TextRun({ text, font: "Calibri", ...opts });
}

function hPara(children, spacing = {}, alignment = AlignmentType.LEFT) {
  return new Paragraph({ children, spacing: { before: 80, after: 80, ...spacing }, alignment });
}

function sectionTitle(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, size: 28, color: WHITE, font: "Calibri" })],
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 300, after: 120 },
    shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
    indent: { left: 200, right: 200 },
  });
}

function subSection(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, size: 24, color: NAVY, font: "Calibri" })],
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 220, after: 80 },
    border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: TEAL } },
  });
}

function subSubSection(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, size: 22, color: TEAL, font: "Calibri" })],
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 160, after: 60 },
  });
}

function bodyText(text) {
  return hPara([hRun(text, { size: 20, color: DARK })], { before: 60, after: 60 });
}

function bullet(text, bold = false, level = 0) {
  return new Paragraph({
    children: [hRun(text, { size: 20, color: DARK, bold })],
    bullet: { level },
    spacing: { before: 40, after: 40 },
  });
}

function noteBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [new TableRow({ children: [new TableCell({
      children: [new Paragraph({
        children: [
          hRun("⚑ Clinical Note: ", { bold: true, size: 19, color: ORANGE }),
          hRun(text, { size: 19, color: DARK, italics: true }),
        ],
        spacing: { before: 60, after: 60 },
        indent: { left: 100 },
      })],
      shading: { type: ShadingType.SOLID, color: "FEF9E7", fill: "FEF9E7" },
      borders: { left: { style: BorderStyle.THICK, size: 12, color: ORANGE } },
      margins: { top: 100, bottom: 100, left: 150, right: 150 },
    })})]},
  ]);
}

function pageBreak() {
  return new Paragraph({ children: [new PageBreak()] });
}

// ── Generic 2-col table ──────────────────────────────────────────
function twoColTable(headers, rows) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map(h => new TableCell({
      children: [new Paragraph({
        children: [hRun(h, { bold: true, size: 19, color: WHITE })],
        spacing: { before: 60, after: 60 },
        indent: { left: 80 },
      })],
      shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
      verticalAlign: VerticalAlign.CENTER,
    })),
  });

  const dataRows = rows.map((row, i) => new TableRow({
    children: row.map(cell => new TableCell({
      children: [new Paragraph({
        children: [hRun(cell, { size: 19, color: DARK })],
        spacing: { before: 50, after: 50 },
        indent: { left: 80 },
      })],
      shading: { type: ShadingType.SOLID, color: i % 2 === 0 ? WHITE : LTGREY, fill: i % 2 === 0 ? WHITE : LTGREY },
    })),
  }));

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
    margins: { top: 50, bottom: 50, left: 80, right: 80 },
  });
}

// ── Multi-col table (flexible) ────────────────────────────────────
function multiColTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) => new TableCell({
      width: colWidths ? { size: colWidths[i], type: WidthType.PERCENTAGE } : undefined,
      children: [new Paragraph({
        children: [hRun(h, { bold: true, size: 18, color: WHITE })],
        spacing: { before: 60, after: 60 },
        indent: { left: 80 },
      })],
      shading: { type: ShadingType.SOLID, color: TEAL, fill: TEAL },
      verticalAlign: VerticalAlign.CENTER,
    })),
  });

  const dataRows = rows.map((row, i) => new TableRow({
    children: row.map((cell, j) => new TableCell({
      width: colWidths ? { size: colWidths[j], type: WidthType.PERCENTAGE } : undefined,
      children: [new Paragraph({
        children: [hRun(cell, { size: 18, color: DARK, bold: j === 0 })],
        spacing: { before: 45, after: 45 },
        indent: { left: 80 },
      })],
      shading: { type: ShadingType.SOLID, color: i % 2 === 0 ? WHITE : LTBLUE, fill: i % 2 === 0 ? WHITE : LTBLUE },
    })),
  }));

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
    margins: { top: 50, bottom: 50, left: 80, right: 80 },
  });
}

// ── DOCUMENT ─────────────────────────────────────────────────────
const doc = new Document({
  creator: "Orris Medical AI",
  title: "IgE-Lowering Therapies: Clinical Treatment Protocol",
  description: "Evidence-based protocol for management of elevated serum IgE",
  styles: {
    default: {
      document: { run: { font: "Calibri", size: 20, color: DARK } },
    },
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 900, bottom: 900, left: 1100, right: 1100 },
      },
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          children: [
            hRun("IgE-Lowering Therapies — Clinical Treatment Protocol", { size: 17, color: NAVY, italics: true }),
            hRun("          Orris Medical AI  |  May 2026", { size: 17, color: "999999" }),
          ],
          border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
          spacing: { after: 100 },
        })],
      }),
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          children: [
            hRun("For clinical use only. Verify dosing against current product labelling.  |  Page ", { size: 16, color: "888888" }),
            new TextRun({ children: [PageNumber.CURRENT], size: 16, color: "888888" }),
            hRun(" of ", { size: 16, color: "888888" }),
            new TextRun({ children: [PageNumber.TOTAL_PAGES], size: 16, color: "888888" }),
          ],
          alignment: AlignmentType.CENTER,
          border: { top: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
        })],
      }),
    },
    children: [

      // ══ COVER ══════════════════════════════════════════════════
      new Paragraph({
        children: [hRun("IgE-Lowering Therapies", { bold: true, size: 56, color: NAVY })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 400, after: 100 },
      }),
      new Paragraph({
        children: [hRun("Clinical Treatment Protocol", { size: 32, color: TEAL, italics: true })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 60 },
      }),
      new Paragraph({
        children: [hRun("Evidence-Based Management of Elevated Serum IgE", { size: 22, color: "666666" })],
        alignment: AlignmentType.CENTER,
        spacing: { before: 0, after: 400 },
      }),

      // divider
      new Table({
        width: { size: 100, type: WidthType.PERCENTAGE },
        rows: [new TableRow({ children: [new TableCell({
          children: [new Paragraph({ children: [] })],
          shading: { type: ShadingType.SOLID, color: TEAL, fill: TEAL },
          borders: { top: { style: BorderStyle.NONE }, bottom: { style: BorderStyle.NONE } },
          height: { value: 40, rule: "exact" },
        })]})],
      }),

      new Paragraph({ children: [], spacing: { before: 200, after: 0 } }),

      // meta info
      twoColTable(["Field", "Details"], [
        ["Document Title", "IgE-Lowering Therapies: Clinical Treatment Protocol"],
        ["Version", "1.0"],
        ["Date", "May 2026"],
        ["Author", "Orris Medical AI"],
        ["Scope", "Allergology, Immunology, Pulmonology, Dermatology"],
        ["Intended Users", "Physicians, clinical pharmacists, immunologists"],
        ["Review Date", "May 2027"],
      ]),

      pageBreak(),

      // ══ 1. PURPOSE & SCOPE ═════════════════════════════════════
      sectionTitle("1.  Purpose & Scope"),
      bodyText("This protocol provides clinicians with a structured, evidence-based framework for the evaluation and management of elevated serum immunoglobulin E (IgE). It covers first-line, second-line, and biologic therapies, organised by underlying aetiology."),
      bodyText("Normal reference range for total serum IgE in adults: < 100–150 IU/mL (varies by assay). Levels above this, in the appropriate clinical context, require systematic investigation before targeted therapy is initiated."),

      new Paragraph({ children: [], spacing: { before: 100 } }),
      noteBox("Elevated IgE is a biomarker, not a diagnosis. Always identify the underlying cause before prescribing IgE-directed therapy."),

      // ══ 2. DIFFERENTIAL DIAGNOSIS ══════════════════════════════
      pageBreak(),
      sectionTitle("2.  Differential Diagnosis of Elevated Serum IgE"),
      bodyText("The following table outlines the major conditions associated with elevated total serum IgE and relevant IgE thresholds:"),
      new Paragraph({ children: [], spacing: { before: 80 } }),

      multiColTable(
        ["Category", "Condition / Aetiology", "Typical IgE Level", "Key Distinguishing Feature"],
        [
          ["Atopic / Allergic", "Allergic asthma", "100–1000 IU/mL", "Allergen-specific IgE positive; spirometry"],
          ["Atopic / Allergic", "Atopic dermatitis", "Up to 10,000 IU/mL", "Chronic eczema; Th2 skewed"],
          ["Atopic / Allergic", "Allergic rhinitis", "100–500 IU/mL", "Seasonal/perennial rhinorrhoea"],
          ["Atopic / Allergic", "Food allergy", "Variable", "Specific IgE to food allergen"],
          ["Fungal", "ABPA (Aspergillus)", "> 1000 IU/mL (essential)", "A. fumigatus IgE/IgG; infiltrates on CXR"],
          ["Parasitic", "Helminth infections", "Very high (> 2000)", "Eosinophilia; travel/exposure history"],
          ["Primary Immunodeficiency", "HIES / Job's syndrome (STAT3)", "> 2000 IU/mL", "Cold abscesses; facial features; eczema"],
          ["Primary Immunodeficiency", "DOCK8 deficiency (AR-HIES)", "> 2000 IU/mL", "Viral susceptibility; cancer risk"],
          ["Primary Immunodeficiency", "Wiskott-Aldrich syndrome", "Elevated", "Thrombocytopenia; small platelets"],
          ["Skin disorder", "Netherton syndrome", "Markedly elevated", "Ichthyosis linearis circumflexa"],
          ["Malignancy", "IgE myeloma (rare)", "Monoclonal IgE", "M-protein on SPEP/serum FLC"],
          ["Other", "CADINS (CARD11 gain-of-function)", "Elevated", "Atopy + recurrent infections"],
        ],
        [18, 22, 18, 42]
      ),

      // ══ 3. DIAGNOSTIC WORK-UP ══════════════════════════════════
      pageBreak(),
      sectionTitle("3.  Diagnostic Work-Up"),

      subSection("3.1  Initial Investigations"),
      multiColTable(
        ["Investigation", "Rationale"],
        [
          ["Total serum IgE (IU/mL)", "Baseline quantification; repeat for monitoring"],
          ["Allergen-specific IgE panel (ImmunoCAP/RAST)", "Identify sensitisation to environmental/food allergens"],
          ["Full blood count with differential", "Eosinophilia: parasites, eosinophilic disorders, HIES"],
          ["Skin-prick testing", "Confirm atopic sensitisation"],
          ["Chest X-ray / HRCT chest", "Infiltrates (ABPA), pneumatoceles (HIES), interstitial disease"],
          ["Stool microscopy & culture", "Helminth ova/larvae if parasitic infection suspected"],
          ["Aspergillus-specific IgE & IgG, Aspergillus precipitins", "Essential for ABPA diagnosis (IgE > 1000 IU/mL + positive)"],
          ["Serum protein electrophoresis (SPEP)", "Exclude IgE myeloma"],
        ],
        [40, 60]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      subSection("3.2  Specialised Immunological Testing (if HIES suspected)"),
      multiColTable(
        ["Test", "Finding in HIES"],
        [
          ["STAT3 gene sequencing", "Heterozygous dominant-negative mutation (AD-HIES)"],
          ["DOCK8 gene sequencing", "Biallelic loss-of-function mutations (AR-HIES)"],
          ["Th17 cell enumeration (flow cytometry)", "Markedly reduced in STAT3-HIES"],
          ["Lymphocyte subset panel", "Reduced CD4+ T cells in DOCK8 deficiency"],
          ["NIH HIES scoring system (Grimbacher score)", "Score ≥ 40 highly suggestive of HIES"],
          ["Immunoglobulin levels (IgG, IgA, IgM)", "Variable; IgM may be reduced in hyper-IgM syndromes"],
        ],
        [40, 60]
      ),

      // ══ 4. TREATMENT ALGORITHM ═════════════════════════════════
      pageBreak(),
      sectionTitle("4.  Treatment Algorithm Overview"),
      bodyText("Management follows a stepwise, aetiology-directed approach. The algorithm below summarises the decision pathway:"),
      new Paragraph({ children: [], spacing: { before: 100 } }),

      multiColTable(
        ["Step", "Action", "Threshold / Criteria"],
        [
          ["Step 1", "Confirm elevated IgE (repeat if borderline)", "Total IgE > 150 IU/mL in adults"],
          ["Step 2", "Identify aetiology (history, examination, investigations per Section 3)", "Mandatory before targeted therapy"],
          ["Step 3A", "Treat underlying cause (allergen avoidance, anthelmintics, antifungals)", "All cases"],
          ["Step 3B", "Initiate disease-specific pharmacotherapy (see Section 5)", "Based on diagnosis"],
          ["Step 4", "Reassess IgE at 3–6 months; escalate to biologic if inadequate control", "IgE-monitored for ABPA; clinical for atopy"],
          ["Step 5", "Consider omalizumab or dupilumab for refractory atopic/allergic disease", "Per eligibility criteria"],
          ["Step 6", "Specialist referral: immunologist (HIES), haematologist (IgE myeloma)", "Diagnosis-specific"],
        ],
        [12, 48, 40]
      ),

      // ══ 5. PHARMACOLOGICAL MANAGEMENT ══════════════════════════
      pageBreak(),
      sectionTitle("5.  Pharmacological Management by Aetiology"),

      // ── 5.1 Atopic Disease
      subSection("5.1  Atopic Disease (Asthma, Atopic Dermatitis, Allergic Rhinitis)"),

      subSubSection("5.1.1  Step-Up Approach — Allergic Asthma (GINA Framework)"),
      multiColTable(
        ["GINA Step", "Controller Therapy", "Reliever"],
        [
          ["Step 1", "As-needed low-dose ICS-formoterol", "As-needed low-dose ICS-formoterol"],
          ["Step 2", "Low-dose ICS daily + as-needed SABA", "SABA as needed"],
          ["Step 3", "Low-dose ICS-LABA", "As-needed SABA or ICS-formoterol"],
          ["Step 4", "Medium/high-dose ICS-LABA", "As-needed SABA or ICS-formoterol"],
          ["Step 5", "High-dose ICS-LABA + omalizumab (if allergic, IgE 30–1500 IU/mL)", "As-needed SABA"],
        ],
        [15, 55, 30]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      subSubSection("5.1.2  Atopic Dermatitis Stepladder"),
      multiColTable(
        ["Severity", "Treatment"],
        [
          ["Mild", "Emollients, topical low-potency corticosteroids (TCS)"],
          ["Moderate", "Moderate-potency TCS; topical calcineurin inhibitors (tacrolimus, pimecrolimus)"],
          ["Moderate–Severe", "Dupilumab (anti-IL-4Rα biologic); oral JAK inhibitors (abrocitinib, upadacitinib)"],
          ["Severe / Refractory", "Cyclosporin (short-term); methotrexate; systemic corticosteroids (rescue only)"],
        ],
        [25, 75]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      subSubSection("5.1.3  Allergic Rhinitis"),
      multiColTable(
        ["Agent", "Route", "Notes"],
        [
          ["Intranasal corticosteroids (mometasone, fluticasone)", "Intranasal", "First-line; most effective"],
          ["Non-sedating antihistamines (cetirizine, fexofenadine, loratadine)", "Oral", "Rapid symptom relief"],
          ["Intranasal antihistamines (azelastine)", "Intranasal", "Alternative to oral"],
          ["Leukotriene receptor antagonists (montelukast)", "Oral", "Adjunct; especially if concomitant asthma"],
          ["Allergen immunotherapy (AIT)", "SC or SL", "Disease-modifying; reduces IgE sensitisation long-term"],
        ],
        [42, 15, 43]
      ),

      // ── 5.2 ABPA
      pageBreak(),
      subSection("5.2  Allergic Bronchopulmonary Aspergillosis (ABPA)"),
      bodyText("ABPA requires total IgE > 1000 IU/mL plus Aspergillus fumigatus sensitisation for diagnosis. Serial IgE is the primary monitoring tool."),
      new Paragraph({ children: [], spacing: { before: 80 } }),
      multiColTable(
        ["Agent", "Dose / Schedule", "Role", "Monitoring"],
        [
          ["Prednisolone (oral)", "0.5 mg/kg/day × 2 weeks, then taper over 6–12 months", "First-line; suppresses Th2 inflammation", "Serial total IgE every 6–8 weeks"],
          ["Itraconazole", "200 mg BD × 16 weeks", "Steroid-sparing; reduces fungal burden", "LFTs, itraconazole levels"],
          ["Voriconazole", "200 mg BD (alternative)", "Second-line antifungal", "Visual disturbances, LFTs"],
          ["Omalizumab", "Per IgE-weight dosing table (SC q2–4 weeks)", "Steroid-sparing biologic; IgE must be ≤ 1500 for standard dosing", "Clinical response at 4 months"],
        ],
        [20, 32, 28, 20]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      noteBox("In ABPA, a 25–35% fall in total IgE from baseline at 6–8 weeks confirms treatment response. A rise in IgE by > 100% during follow-up indicates relapse requiring re-treatment."),

      // ── 5.3 Biologics
      pageBreak(),
      subSection("5.3  Biologic Therapies Targeting the IgE Axis"),

      subSubSection("5.3.1  Omalizumab (Anti-IgE Monoclonal Antibody)"),
      bodyText("Omalizumab is a humanised IgG1 monoclonal antibody that binds the Cε3 domain of free IgE, preventing binding to high-affinity (FcεRI) and low-affinity (FcεRII/CD23) receptors on mast cells, basophils, B cells, and dendritic cells."),

      new Paragraph({ children: [], spacing: { before: 100 } }),
      multiColTable(
        ["Parameter", "Details"],
        [
          ["Mechanism", "Binds free IgE → prevents mast cell/basophil activation; downregulates FcεRI expression; enhances anti-viral IFN-I response"],
          ["Approved Indications", "Severe allergic asthma (IgE 30–1500 IU/mL); chronic spontaneous urticaria; ABPA (off-label); nasal polyps"],
          ["Dosing", "Subcutaneous injection q2–4 weeks; dose (75–600 mg) determined by baseline total IgE (IU/mL) and body weight (kg) — see dosing table"],
          ["Eligibility", "Confirmed atopic sensitisation; IgE 30–1500 IU/mL; weight 20–150 kg; inadequate control on standard therapy"],
          ["Response Assessment", "Clinical evaluation at 16 weeks; high eosinophil count and elevated FeNO predict better response"],
          ["Efficacy", "> 50% excellent clinical response in severe allergic asthma; reduces exacerbations by ~25–50%"],
          ["Duration", "Continue if clear clinical benefit at 16-week assessment; no defined upper limit"],
          ["Adverse Effects", "Anaphylaxis (< 0.1%) — observe 30–60 minutes post-injection; injection-site reactions; arthralgia"],
          ["Monitoring", "Clinical symptoms; asthma control questionnaire (ACQ); peak flow; FeNO; note: total IgE rises during therapy — unreliable for monitoring response"],
        ],
        [30, 70]
      ),

      new Paragraph({ children: [], spacing: { before: 160 } }),
      subSubSection("5.3.2  Omalizumab Dosing Reference Table"),
      bodyText("Dose is determined by baseline total IgE (IU/mL) measured BEFORE initiation and body weight:"),
      new Paragraph({ children: [], spacing: { before: 80 } }),
      multiColTable(
        ["Baseline IgE (IU/mL)", "Body Weight ≤ 30 kg", "31–60 kg", "61–90 kg", "91–150 kg"],
        [
          ["≥ 30 – ≤ 100", "75 mg q4w", "150 mg q4w", "150 mg q4w", "300 mg q4w"],
          ["> 100 – ≤ 200", "150 mg q4w", "300 mg q4w", "300 mg q4w", "225 mg q2w"],
          ["> 200 – ≤ 300", "150 mg q4w", "300 mg q4w", "225 mg q2w", "300 mg q2w"],
          ["> 300 – ≤ 400", "225 mg q2w", "225 mg q2w", "300 mg q2w", "Do not use"],
          ["> 400 – ≤ 500", "225 mg q2w", "300 mg q2w", "375 mg q2w", "Do not use"],
          ["> 500 – ≤ 600", "300 mg q2w", "300 mg q2w", "Do not use", "Do not use"],
          ["> 600 – ≤ 700", "300 mg q2w", "375 mg q2w", "Do not use", "Do not use"],
          ["> 700 – ≤ 1500", "375 mg q2w", "Do not use", "Do not use", "Do not use"],
          ["> 1500", "Do not use", "Do not use", "Do not use", "Do not use"],
        ],
        [25, 19, 19, 19, 18]
      ),

      new Paragraph({ children: [], spacing: { before: 160 } }),
      subSubSection("5.3.3  Dupilumab (Anti-IL-4Rα)"),
      bodyText("Dupilumab blocks the shared IL-4/IL-13 receptor alpha subunit, suppressing Th2-driven inflammation. It reduces IgE production as a downstream effect."),
      new Paragraph({ children: [], spacing: { before: 80 } }),
      multiColTable(
        ["Parameter", "Details"],
        [
          ["Mechanism", "Blocks IL-4Rα → inhibits IL-4 and IL-13 signalling → reduces IgE synthesis, Th2 differentiation, eosinophil recruitment"],
          ["Approved Indications", "Moderate-severe atopic dermatitis; severe eosinophilic or OCS-dependent asthma; chronic rhinosinusitis with nasal polyps; eosinophilic oesophagitis; prurigo nodularis"],
          ["Dosing — Atopic Dermatitis (adult)", "600 mg SC loading dose, then 300 mg SC q2w (or 300 mg q4w in mild-moderate disease on TCS)"],
          ["Dosing — Asthma (adult)", "400 mg SC loading, then 200 mg q2w; or 600 mg SC loading, then 300 mg q2w (eosinophilic)"],
          ["Use in HIES", "Reported to improve eczematous dermatitis in both STAT3-HIES and DOCK8 deficiency"],
          ["Key Adverse Effects", "Conjunctivitis (most common); injection-site reactions; transient eosinophilia (monitor); arthralgia"],
          ["Monitoring", "EASI/SCORAD for AD; ACQ/FEV₁ for asthma; eye examination if conjunctivitis"],
        ],
        [28, 72]
      ),

      new Paragraph({ children: [], spacing: { before: 160 } }),
      subSubSection("5.3.4  Other Biologics (Indirect IgE Reduction via Th2 Pathway)"),
      multiColTable(
        ["Biologic", "Target", "Indication", "Dosing"],
        [
          ["Mepolizumab", "IL-5", "Severe eosinophilic asthma; EGPA; HES", "100 mg SC q4w"],
          ["Benralizumab", "IL-5Rα", "Severe eosinophilic asthma", "30 mg SC q4w × 3, then q8w"],
          ["Reslizumab", "IL-5", "Severe eosinophilic asthma (≥ 400 eosinophils/µL)", "3 mg/kg IV q4w"],
          ["Tezepelumab", "TSLP", "Severe uncontrolled asthma (broader phenotype)", "210 mg SC q4w"],
          ["Tralokinumab", "IL-13", "Moderate-severe atopic dermatitis", "600 mg SC loading, then 300 mg q2w"],
          ["Lebrikizumab", "IL-13", "Moderate-severe atopic dermatitis", "500 mg SC × 2 at wk 0, then 250 mg q2w"],
        ],
        [20, 15, 35, 30]
      ),

      // ── 5.4 Parasitic
      pageBreak(),
      subSection("5.4  Parasitic Infection"),
      bodyText("Helminth infections are a major global cause of markedly elevated IgE (> 2000 IU/mL). Anti-IgE biologics have no role — treat the underlying infection."),
      new Paragraph({ children: [], spacing: { before: 80 } }),
      multiColTable(
        ["Organism", "Drug of Choice", "Dose", "Notes"],
        [
          ["Ascaris, hookworm, Trichuris (STH)", "Albendazole", "400 mg single dose (≥ 2 years)", "Repeat at 2 weeks if heavy burden"],
          ["Strongyloides stercoralis", "Ivermectin", "200 µg/kg/day × 2 days", "Immunocompromised: treat until negative stool × 2"],
          ["Schistosoma spp.", "Praziquantel", "40 mg/kg/day in 2 divided doses", "Single-day treatment"],
          ["Toxocara canis (visceral larva migrans)", "Albendazole", "400 mg BD × 5 days", "Corticosteroid adjunct if severe organ involvement"],
          ["Echinococcus granulosus", "Albendazole", "400 mg BD (weight-based) + surgery/PAIR", "Long-term; specialist management required"],
        ],
        [25, 20, 27, 28]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      noteBox("IgE levels may transiently rise during helminth treatment due to parasite antigen release, then normalise over 6–12 months. Follow-up IgE and eosinophilia are expected to fall progressively."),

      // ── 5.5 HIES
      pageBreak(),
      subSection("5.5  Hyper-IgE Syndrome (HIES / Job's Syndrome)"),
      bodyText("HIES is a rare primary immunodeficiency (PID) caused predominantly by dominant-negative STAT3 mutations. Management is multidisciplinary. There is no specific IgE-lowering therapy; the goals are infection prevention, skin control, and consideration of curative HSCT in severe cases."),
      new Paragraph({ children: [], spacing: { before: 80 } }),

      subSubSection("5.5.1  Infection Prophylaxis & Treatment"),
      multiColTable(
        ["Intervention", "Indication", "Detail"],
        [
          ["TMP-SMX (trimethoprim-sulfamethoxazole)", "Prophylaxis: all HIES patients", "160/800 mg BD orally"],
          ["Itraconazole / Voriconazole / Fluconazole", "Mucocutaneous candidiasis; pulmonary aspergillosis", "Choice depends on site and severity"],
          ["Anti-staphylococcal antibiotics (cloxacillin, clindamycin)", "Staphylococcal skin/soft tissue infections", "Prolonged courses often required"],
          ["Incision & drainage", "Cold abscesses", "Mandatory — I&D alone insufficient; combine with antibiotics"],
          ["Recombinant IFN-γ (50 µg/m² SC 3×/week)", "Refractory infections; useful in CGD overlap", "Evidence from CGD extrapolated to HIES"],
        ],
        [32, 30, 38]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      subSubSection("5.5.2  IgE-Targeted & Immune-Modulating Therapy"),
      multiColTable(
        ["Agent", "Mechanism / Role", "Evidence Level"],
        [
          ["Intravenous immunoglobulin (IVIg)", "Reduces infections; may lower IgE levels; improves dermatitis", "Case series / expert opinion"],
          ["Dupilumab", "Improves eczematous dermatitis in STAT3-HIES and DOCK8 deficiency", "Case reports / small series"],
          ["Omalizumab", "Reported to improve eczematous dermatitis", "Case reports"],
          ["Cyclosporin", "Reported benefit in small case series (hyper-IgE syndrome)", "Case series (limited)"],
          ["HSCT (haematopoietic stem cell transplantation)", "Potentially curative for DOCK8 deficiency; outcomes improving for AR-HIES", "Cohort studies"],
          ["JAK inhibitors (e.g., ruxolitinib)", "Under investigation: targets STAT3 pathway", "Early-phase / investigational"],
        ],
        [25, 50, 25]
      ),

      // ══ 6. MONITORING ══════════════════════════════════════════
      pageBreak(),
      sectionTitle("6.  Monitoring & Follow-Up"),
      multiColTable(
        ["Condition", "Monitoring Parameter", "Frequency", "Action if No Response"],
        [
          ["Allergic asthma", "ACQ score, FEV₁, exacerbation rate", "Every 3 months", "Step up therapy; consider biologic"],
          ["Atopic dermatitis", "EASI / SCORAD / IGA score, pruritus NRS", "Every 4–8 weeks on biologic", "Switch biologic class"],
          ["ABPA", "Total serum IgE (IU/mL)", "Every 6–8 weeks", "Relapse if IgE rises > 100% — restart steroids"],
          ["HIES (monitoring)", "Total IgE, CBC differential, Th17 count", "Every 6 months", "Escalate infection prophylaxis; consider HSCT referral"],
          ["Parasitic infection", "Stool microscopy, total IgE, eosinophil count", "6–12 weeks post-treatment", "Re-treat if stool positive; check for re-exposure"],
          ["Omalizumab therapy", "Clinical response, ACQ, peak flow", "At 16 weeks", "Discontinue if no clear benefit"],
          ["Dupilumab therapy", "EASI, ACQ, FEV₁, eye examination", "Every 12–16 weeks", "Adjust dose; review diagnosis"],
        ],
        [18, 25, 18, 39]
      ),

      new Paragraph({ children: [], spacing: { before: 120 } }),
      noteBox("Total IgE measured DURING omalizumab therapy is falsely elevated (reflects bound + free IgE complexes) and cannot be used to assess treatment response. Use clinical endpoints instead."),

      // ══ 7. SPECIAL POPULATIONS ═════════════════════════════════
      pageBreak(),
      sectionTitle("7.  Special Populations"),
      multiColTable(
        ["Population", "Considerations"],
        [
          ["Children (< 6 years)", "Omalizumab approved ≥ 6 years (asthma); dupilumab approved ≥ 6 months (AD). Weight-based omalizumab dosing. HIES: early genetic diagnosis critical."],
          ["Pregnancy", "Omalizumab: limited data; consider benefit–risk in severe asthma. Dupilumab: not recommended. Biologics cross placenta in 3rd trimester. Anthelmintics (albendazole): avoid 1st trimester."],
          ["Elderly (> 65 years)", "Reduced renal clearance may affect cyclosporin dosing. Monitor for infection risk with biologics."],
          ["Immunocompromised patients", "Strongyloides hyperinfection can be fatal — screen and treat prophylactically before immunosuppression. Avoid live vaccines during biologic therapy."],
          ["Patients with IgE myeloma", "Refer to haematology. Plasma cell-directed therapy (bortezomib-based regimens) is primary treatment. Anti-IgE biologics not indicated."],
          ["HIES + pregnancy", "No established protocols. Multidisciplinary approach. Continue infection prophylaxis; individualize biologic use."],
        ],
        [22, 78]
      ),

      // ══ 8. SUMMARY TABLE ═══════════════════════════════════════
      pageBreak(),
      sectionTitle("8.  Quick Reference Summary"),
      multiColTable(
        ["Condition", "First-Line Therapy", "IgE-Directed Biologic", "Key Monitoring"],
        [
          ["Allergic asthma", "Inhaled ICS ± LABA", "Omalizumab (IgE 30–1500)", "ACQ, FEV₁, exacerbation rate"],
          ["Atopic dermatitis", "Topical CS + emollients", "Dupilumab; omalizumab", "EASI / SCORAD"],
          ["Allergic rhinitis", "Intranasal CS + antihistamine", "Allergen immunotherapy", "Symptom scores, RQLQ"],
          ["ABPA", "Oral prednisolone + itraconazole", "Omalizumab (steroid-sparing)", "Serial total IgE q6–8 weeks"],
          ["Helminth infection", "Anthelmintic (albendazole/ivermectin)", "Not applicable", "Stool + IgE + eosinophils"],
          ["HIES (Job's syndrome)", "TMP-SMX prophylaxis + antifungals", "Dupilumab, IVIg, omalizumab", "Infection frequency; IgE trend"],
          ["Anaphylaxis (prevention)", "Epinephrine auto-injector + trigger avoidance", "Omalizumab (adjunct in selected)", "Clinical + self-report"],
          ["Chronic urticaria", "Non-sedating antihistamines (4× standard dose)", "Omalizumab (300 mg q4w)", "UAS7 weekly symptom score"],
        ],
        [22, 26, 26, 26]
      ),

      // ══ 9. REFERENCES ══════════════════════════════════════════
      pageBreak(),
      sectionTitle("9.  Key References"),
      bullet("Harrison's Principles of Internal Medicine, 22nd Edition (2025). McGraw Hill. Chapter 67: Hyperimmunoglobulin E-Recurrent Infection Syndrome.", false),
      bullet("Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition. Chapter 44: Anti-IgE and Anti-IL-5 Therapies.", false),
      bullet("Dermatology, 5th Edition (Griffiths et al., Elsevier 2022). Chapter 60: Hyperimmunoglobulin E Syndromes.", false),
      bullet("Janeway's Immunobiology, 10th Edition. Chapter 14: Allergy and Allergic Disease — Treatments for Allergic Disease.", false),
      bullet("Roitt's Essential Immunology, 13th Edition. Deficiencies Leading to Dysfunctional T-cell–B-cell Collaboration.", false),
      bullet("GINA Report 2024: Global Strategy for Asthma Management and Prevention. ginasthma.org", false),
      bullet("Bachert C et al. Dupilumab for chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019.", false),
      bullet("Vignoli M et al. Omalizumab in ABPA: a systematic review. Clin Exp Allergy. 2022.", false),
      bullet("Mahjoubi M et al. Dermatologic presentations of hyper IgE syndrome in pediatric patients. Allergy Asthma Clin Immunol. 2025. PMID: 40317072", false),
      bullet("WHO Guidelines for treatment of soil-transmitted helminthiases in high-risk groups, 2017.", false),

      new Paragraph({ children: [], spacing: { before: 300 } }),
      new Paragraph({
        children: [hRun("End of Protocol — Version 1.0 | May 2026 | Orris Medical AI", { size: 18, color: "999999", italics: true })],
        alignment: AlignmentType.CENTER,
        border: { top: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
        spacing: { before: 200 },
      }),

    ],
  }],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync("/home/daytona/workspace/ige-protocol/IgE_Treatment_Protocol.docx", buffer);
  console.log("Document created successfully.");
}).catch(err => {
  console.error("Error:", err);
  process.exit(1);
});

Running Command

cd /home/daytona/workspace/ige-protocol && node generate.js

Reading File

Editing File

~/ige-protocol/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/ige-protocol/generate.js'

Running Command

cd /home/daytona/workspace/ige-protocol && node generate.js

Running Command

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

Running Command

ls -lh /home/daytona/workspace/ige-protocol/IgE_Treatment_Protocol.docx && pytho…

Your document is ready:

IgE Treatment Protocol

Word Document · DOCX

What's inside the protocol (9 sections):

Section	Content
1. Purpose & Scope	Clinical context, normal IgE reference ranges, key caveat
2. Differential Diagnosis	Full table: 12 conditions with typical IgE levels and distinguishing features
3. Diagnostic Work-Up	Initial investigations + specialised immunological testing (HIES workup, Grimbacher score)
4. Treatment Algorithm	6-step stepwise decision pathway
5. Pharmacological Management	By aetiology: allergic asthma (GINA step-up), atopic dermatitis ladder, ABPA, biologics (omalizumab + dosing table, dupilumab, anti-IL-5s, tezepelumab, tralokinumab), helminths, HIES
6. Monitoring & Follow-Up	Condition-specific parameters, frequency, and escalation triggers
7. Special Populations	Children, pregnancy, elderly, immunocompromised, IgE myeloma
8. Quick Reference Summary	Single-table overview of all conditions
9. References	Key textbooks and PubMed citations

The document includes professional formatting with a navy/teal colour scheme, clinical note callout boxes, a branded header/footer with page numbers, and all drug dosing tables.

This is a shared conversation. Sign in to Orris to start your own chat.